|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | No. of studies | No. of experimental group | No. of control group | RR | 95% CI | *p* | Heterogeneity |
| (I2) (%) |
| Alopecia | 5 | 1795 | 1267 | 0.87 | 0.67-1.13 | 0.31 | 83 |
| Anemia | 6 | 1842 | 1302 | 0.97 | 0.95-1.24 | 0.79 | 69 |
| Cough | 4 | 1233 | 986 | 1.39 | 1.14-1.69 | *0.001* | 0 |
| Diarrhoea | 5 | 1280 | 1021 | 0.88 | 0.64-1.19 | 0.39 | 71 |
| Dyspnea | 5 | 1280 | 1201 | 1.11 | 0.87-1.41 | 0.39 | 0 |
| Fatigue | 6 | 1842 | 1302 | 1.02 | 0.92-1.13 | 0.75 | 0 |
| Hyperthyroidism | 3 | 773 | 556 | 15.17 | 5.77-39.83 | *<0.001* | 0 |
| Hypothyroidism | 6 | 1842 | 1302 | 3.85 | 2.78-5.32 | *<0.001* | 0 |
| Nausea | 5 | 1795 | 1267 | 0.92 | 0.71-1.19 | 0.52 | 80 |
| Neutropenia | 5 | 1410 | 1085 | 0.76 | 0.41-1.40 | 0.38 | 83 |
| Pneumonia | 5 | 1795 | 1267 | 2.95 | 1.67-5.22 | *<0.001* | 0 |
| Pyrexia | 5 | 1280 | 1201 | 1.40 | 0.93-2.12 | 0.11 | 44 |

**Supplementary Table 3.** Subgroup analysis of the AEs (any grade) of of unresectable locally advanced or metastatic triple negative breast cancer (TNBC) with programmed cell death protein 1/programmed apoptosis ligand 1 (PD-1/PD-L1) inhibitor based immunotherapy combined with chemotherapy, versus other treatments

PD-1/PD-L1: PD-1/PD-L1: programmed cell death protein 1/programmed cell death 1 ligand 1; AEs: adverse events; RR: risk ratio; Cl: confidence interval